Q-Line Biotech IPO Financials
The Q-Line Biotech IPO provide an overview of the company's performance over the previous financial periods. Investors can evaluate key financial metrics such as assets, revenue, profit after tax (PAT), net worth, reserves & surplus, and total borrowings to assess the company's financial strength, profitability, and long-term growth potential before investing in the IPO.
As of 31 Dec 2025, Q-Line Biotech Limited reported assets of ₹561.34 crore, revenue of ₹236.5 crore, and a profit after tax (PAT) of ₹38.69 crore. The company had a net worth of ₹-0.04 crore and reserves & surplus of ₹2,12,88,920 crore, and total borrowings are 243.85 crore.
Revenue increased by 36.40% in 31 Mar 2025 and decreased by 36.00% in 31 Mar 2024 and decreased by 10.48% in 31 Mar 2023, while Profit After Tax (PAT) declined by 27.29% in 31 Mar 2025 and grew by 22.43% in 31 Mar 2024 and declined by 6.79% in 31 Mar 2023, respectively.
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
Q-Line Biotech Limited Financials (₹ in Crores)
| Particular | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 561.34 | 455.49 | 339.25 | 251.58 |
| Revenue | 236.5 | 322.58 | 206.45 | 184.81 |
| Profit After Tax | 38.69 | 28.13 | 34.44 | 32.1 |
| Net Worth | -0.04 | 189.95 | 161.81 | 127.37 |
| Reserve & Surplus | 21288920 | 188.37 | 160.24 | 125.79 |
| Total Borrowings | 243.85 | 164.95 | 96.91 | 73.65 |
EPS Pre
16.47%
EPS Post
22.12%
P/E Pre
20.82
P/E (Post Issue)
15.51x
Company Financial Information
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Revenue of Q-Line Biotech Limited?
Q-Line Biotech Limited reported revenue of ₹236.5 crore as of 31 Dec 2025. Revenue figures from the Q-Line Biotech IPO provide insights into sales growth, market demand, and business scalability.
What is the Profit After Tax (PAT) of Q-Line Biotech Limited?
Q-Line Biotech Limited reported a Profit After Tax (PAT) of ₹38.69 crore as of 31 Dec 2025. PAT represents the company's net profit after deducting all operating expenses, interest, taxes, and other applicable charges, making it a key indicator of overall profitability.
What is the PE Ratio of Q-Line Biotech Limited?
Q-Line Biotech Limited has a Price-to-Earnings (P/E) ratio of 20.82x based on the IPO issue price. The P/E ratio compares the company's share price with its earnings per share (EPS) and is a commonly used valuation metric to assess whether a stock is fairly valued relative to its earnings and industry peers.